# Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis

> **NCT02337608** · PHASE2 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 64 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** GLPG1205
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02337608
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-09
- **Final completion:** 2015-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2015-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02337608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02337608, "Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02337608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*